Under construction – not a live service
Sign in
Not yet taking people in MexicoNo phase

Following how finerenone affects kidney health in primary care patients with diabetes

Observes finerenone use in adults with type 2 diabetes and kidney disease.

Key facts

Who runs it
Bayer
Where
Many Locations, MexicoSee the site
Trial code
Registry title
A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)
Status
Not yet recruiting
People taking part
800 people, planned
Starts
30 Nov 2026
Expected to end
31 Jan 2028
Type of study
Observational
Treatments tested
  • Finerenone
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes and chronic kidney disease whose primary care doctor has already decided to start finerenone as part of usual care.

Age
18 years or older
Sex
All genders
Disease stage
Type 2 diabetes and chronic kidney disease stages G2 to G3b (eGFR 30 or more and below 90 mL/min/1.73 m^2), with a urinary albumin-to-creatinine ratio (uACR) of 30 mg/g or more
Earlier treatment
The doctor must have decided to start finerenone as part of routine care, within the approved use.
Biomarker or test result
Baseline uACR of 30 mg/g or more; serum potassium below 5.0 mmol/L

Main reasons for not taking part

  • Taking part in another interventional clinical study during follow-up
  • Any contraindication to finerenone under the local label

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Adult participant - all genders (>=18 years old)
  • Documented diagnosis of Type 2 diabetes (T2D), according to clinical criteria used in routine clinical practice
  • Documented diagnosis of Chronic Kidney Disease (CKD) in stages G2 to G3b, defined by an estimated glomerular filtration rate (Estimated Glomerular Filtration Rate [eGFR] >=30 and <90 mL/min/1.73 m\^2 according to the information available in the clinical record)
  • Baseline urinary albumin-to-creatinine ratio (uACR) value >=30 mg/g, documented at the time of inclusion in the study
  • Decision to initiate treatment with finerenone made by the physician as part of his or her routine clinical practice and independently of the patient's inclusion in the study
  • Baseline serum potassium <5.0 mmol/L, determined prior to or at the time of inclusion in the study
  • Signed informed consent
  • Prescription of finerenone within the authorized indications and in accordance with the prescribing information in force in the local market
  • No contraindications to the use of finerenone, in accordance with local marketing authorization and prescribing information in force

Who cannot take part

  • Concomitant participation in an interventional clinical study involving interventions outside of routine clinical practice at any time during the follow-up period of the present study
  • Contra-indications according to the local label

Where in Mexico

  • Many LocationsMany Locations, MexicoNo longer taking part

About the trial

What the trial wants to find out

The main purpose of this study is to learn how treatment with finerenone affects the urinary albumin-to-creatinine ratio (uACR), a marker of kidney health, over time in adults with type 2 diabetes and chronic kidney disease who are receiving care in primary care clinics as part of their usual medical care. The study will help researchers better understand how finerenone is used and how people respond to treatment in everyday primary care settings.

Read full original descriptionShow less

This is an observational study, which means the study does not decide or assign treatment. Participants will receive finerenone only if their primary care doctor has already decided to prescribe it as part of routine medical care. The doctor will determine the starting dose and make any dose changes based on the participant's individual needs.

All participants will be enrolled in a single study group and followed for up to 12 months after starting finerenone. Information collected during routine primary care visits may include kidney health measurements, laboratory test results, other medications, healthcare use, and any side effects experienced during treatment. Follow-up assessments are planned around Month 1, Month 3, Month 6, and Month 12. Information about adverse events will be collected until 30 days after the participant's last dose of finerenone. The study will not require additional treatment decisions beyond routine care and aims to understand how finerenone performs in real-world primary care practice.

The group in the trial

  • Finerenone

    Patients initiate finerenone according to routine clinical practice.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Clinical Profile, Treatment Patterns and Evolution of the Urinary Albumin-to-creatinine Ratio in Patients With Type 2 Diabetes and Chronic Kidney Disease Treated With Finerenone at the Primary Care of the IMSS: Observational, Prospective, Multicenter Study
Plain-language title
Following how finerenone affects kidney health in primary care patients with diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
12 November 2026